FDA approves NPS drug, in move validating Shire takeover deal

January 24, 2015 12:02 AM

14 0

(Reuters) - The U.S. Food and Drug Administration has approved NPS Pharmaceuticals Inc.'s drug Natpara to treat a rare hormone disorder, validating a bet by Shire Plc, which recently agreed to acquire NPS for $5.2 billion.

Natpara is designed to treat hypoparathyroidism, a condition in which the body's parathyroid gland does not secrete enough parathyroid hormone (PTH). The hormone works with vitamin D to regulate body calcium.

Also read: Chipmaker SK Hynix reports 64 percent jump in 1Q earnings

Read more

To category page